AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38709718 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AA-AA-AA-AA-A)
Number of subjects: 5340
Study 38709718 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (PP-PP-AA-AA-A)
Number of subjects: 5340
Study 38709718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (AA-AA-AA-PP-P)
Number of subjects: 5340
Study 38709718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PP-PP-AA-PP-P)
Number of subjects: 5340
Study 38709746 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS-PD intervention alongside standard care
Number of subjects: 88
Study 38709746 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 88
Study 38709803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cube containing vitamin A, folic acid, vitamin B12, iron, zinc, and iodine
Number of subjects: 0
Study 38709803 — intervention group
Group type: COMPARATOR
Intervention: Control bouillon cube containing iodine only
Number of subjects: 0
Study 38709803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cube
Number of subjects: 0
Study 38709803 — intervention group
Group type: COMPARATOR
Intervention: Control bouillon cube
Number of subjects: 0
Study 38709986 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg once daily for 6 weeks, titrated to 10 mg once daily for 18 weeks)
Number of subjects: 276
Study 38709986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 38709986 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 276
Study 38709999 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) selected by noncontrast CT (NCCT)
Number of subjects: 839
Study 38709999 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 839
Study 38710003 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 246
Study 38710003 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 246
Study 38710003 — intervention group
Group type: COMPARATOR
Intervention: PF
Number of subjects: 246
Study 38710013 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal activity (allowed to resume activity at their discretion)
Number of subjects: 158
Study 38710013 — intervention group
Group type: COMPARATOR
Intervention: Restricted activity (avoidance of strenuous exercise and heavy lifting)
Number of subjects: 158
Study 38710013 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal activity
Number of subjects: 158
Study 38710013 — intervention group
Group type: COMPARATOR
Intervention: Restricted activity
Number of subjects: 158
Study 38710048 — intervention group
Group type: EXPERIMENTAL
Intervention: Consilium Care app (ePROs)
Number of subjects: 178
Study 38710048 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy subgroup (Consilium Care app)
Number of subjects: 178
Study 38710048 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched retrospective data)
Number of subjects: 178
Study 38710093 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound of the temporal artery as a first-line diagnostic test
Number of subjects: 165
Study 38710093 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal artery biopsy (TAB) as a secondary test
Number of subjects: 165
Study 38710093 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical expertise and/or other imaging tests
Number of subjects: 165
Study 38710093 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound of the temporal artery
Number of subjects: 165
Study 38710093 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative diagnosis
Number of subjects: 165
Study 38710185 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab 200 mg once monthly
Number of subjects: 38
Study 38710185 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab 600 mg once monthly
Number of subjects: 38
Study 38710185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 38710187 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5.4 mg/kg every 3 weeks by intravenous infusion)
Number of subjects: 102
Study 38710187 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 102
Study 38710192 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster subunit vaccine (0.5 mL intramuscular injection) at weeks 0 and 8
Number of subjects: 65
Study 38710192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mL intramuscular injection) at weeks 0 and 8
Number of subjects: 65
Study 38710192 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster subunit vaccine
Number of subjects: 65
Study 38710192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 38710192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 38710269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g conjugated estrogen cream (0.625 mg/g), inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively
Number of subjects: 206
Study 38710269 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream, inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively
Number of subjects: 206
Study 38710269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g conjugated estrogen cream (0.625 mg/g)
Number of subjects: 206
Study 38710269 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 206
Study 38710269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (estrogen and placebo)
Number of subjects: 206
Study 38710269 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen group
Number of subjects: 206
Study 38710269 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 206
Study 38710268 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient grading of adverse events (mild, moderate, severe/very severe/life-threatening)
Number of subjects: 360
Study 38710268 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient grading of adverse events
Number of subjects: 360
Study 38710268 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial patient grading of the most severe reported adverse event
Number of subjects: 360
Study 38710268 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial grading of 'severe' adverse events
Number of subjects: 360
Study 38710268 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient grading of adverse events over time
Number of subjects: 360
Study 38710323 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of cerebral oxygenation based on regional cerebral oxygen saturation (rSO2) monitoring
Number of subjects: 879
Study 38710323 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 879
Study 38710325 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ketamine 0.5 mg/kg intravenous bolus
Number of subjects: 301
Study 38710325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 38710379 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 774
Study 38710379 — intervention group
Group type: COMPARATOR
Intervention: No-touch (NT) vein graft
Number of subjects: 774
Study 38710426 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous telerehabilitation
Number of subjects: 35
Study 38710426 — intervention group
Group type: COMPARATOR
Intervention: Booklet-based rehabilitation
Number of subjects: 35
Study 38710437 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNACT intervention (exercise, education, psychological and nutrition)
Number of subjects: 110
Study 38710437 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care (control)
Number of subjects: 110
Study 38710445 — intervention group
Group type: COMPARATOR
Intervention: HSP+ (45 g HSP + 5 g HSP-derived bioactive peptides/d)
Number of subjects: 35
Study 38710445 — intervention group
Group type: COMPARATOR
Intervention: HSP (50 g HSP/d)
Number of subjects: 35
Study 38710445 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (50 g casein/d)
Number of subjects: 35
Study 38710463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural tPA and deoxyribonuclease
Number of subjects: 10
Study 38710487 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg once daily (QD) 3 days on, 4 days off (160 3/4)
Number of subjects: 119
Study 38710487 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg QD 3 days on, 4 days off (120 3/4)
Number of subjects: 119
Study 38710487 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg QD 3 days on, 4 days off, 2 weeks on, 1 week off (160 3/4, 2/1w)
Number of subjects: 119
Study 38710537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate sodium (137 mEq/L)
Number of subjects: 29
Study 38710537 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate sodium (140 mEq/L)
Number of subjects: 29
Study 38710539 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 2371
Study 38710539 — intervention group
Group type: COMPARATOR
Intervention: Traditional systemic treatment
Number of subjects: 2371
Study 38710539 — intervention group
Group type: COMPARATOR
Intervention: Nonsystemic treatment
Number of subjects: 2371
Study 38710539 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2371
Study 38710539 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing psoriatic lesions
Number of subjects: 2371
Study 38710539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2371
Study 38710583 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive non-surgical therapy (MINST)
Number of subjects: 84
Study 38710641 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM custom-milled allogeneic bone blocks (CCBB)
Number of subjects: 19
Study 38710641 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated allogeneic bone blocks (PBB)
Number of subjects: 19
Study 38710669 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement with contemporary surgical aortic valves (10 valve models, all tissue valves; n=2938 patients)
Number of subjects: 2958
Study 38710888 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent tacks
Number of subjects: 338
Study 38710888 — intervention group
Group type: COMPARATOR
Intervention: Absorbable tacks
Number of subjects: 338
Study 38710920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuvastatic™ 1000 mg thrice daily for 9 weeks
Number of subjects: 110
Study 38710920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 38710951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 107
Study 38710966 — intervention group
Group type: EXPERIMENTAL
Intervention: SCACOMS (Spinocerebellar Ataxia Composite Scale)
Number of subjects: 0
Study 38710966 — intervention group
Group type: EXPERIMENTAL
Intervention: SCACOMS-derived estimate
Number of subjects: 0
Study 38710978 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric high-fat diet (HFD) for one month
Number of subjects: 18
Study 38710996 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine (650 mg/m² twice daily for 1 year)
Number of subjects: 28
Study 38711010 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading
Number of subjects: 34
Study 38711010 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative fasting
Number of subjects: 34
Study 38711048 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME intervention (intervention group)
Number of subjects: 150
Study 38711048 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 150
Study 38711112 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 166
Study 38711112 — intervention group
Group type: COMPARATOR
Intervention: Point-of-care (POC) glucose testing
Number of subjects: 166
Study 38711161 — intervention group
Group type: EXPERIMENTAL
Intervention: Muller maneuver
Number of subjects: 21
Study 38711161 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 21
Study 38711161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing
Number of subjects: 21
Study 38711161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 21
Study 38711161 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea
Number of subjects: 21
Study 38711161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement
Number of subjects: 21
Study 38711198 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics combined with a conventional plaque morphological and compositional metric-based model
Number of subjects: 55
Study 38711198 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic model alone
Number of subjects: 55
Study 38711198 — intervention group
Group type: COMPARATOR
Intervention: Conventional model alone
Number of subjects: 55
Study 38711253 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus azacitidine (75 mg/m²)
Number of subjects: 60
Study 38711253 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus decitabine
Number of subjects: 60
Study 38711376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated rTMS
Number of subjects: 10
Study 38711376 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 10
Study 38711376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rTMS and Sham
Number of subjects: 10
Study 38711791 — intervention group
Group type: EXPERIMENTAL
Intervention: PH group
Number of subjects: 504
Study 38711791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study 38711834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygenation target
Number of subjects: 563
Study 38711834 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygenation target
Number of subjects: 563
Study 38711854 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin + pembrolizumab
Number of subjects: 0
Study 38712133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib tosylate, valproic acid, and sildenafil
Number of subjects: 33
Study 38712176 — intervention group
Group type: COMPARATOR
Intervention: Consolidation doublet chemotherapy (mFOLFOX6 or CAPOX) after neoadjuvant long course chemoradiation (LCRT)
Number of subjects: 760
Study 38712176 — intervention group
Group type: COMPARATOR
Intervention: Consolidation triplet chemotherapy (mFOLFIRINOX) after neoadjuvant long course chemoradiation (LCRT)
Number of subjects: 760
Study 38712176 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (Phase III portion)
Number of subjects: 760
Study 38712176 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (Secondary objectives)
Number of subjects: 760
Study 38712567 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT (anti-hypotensive therapy)
Number of subjects: 66
Study 38712567 — intervention group
Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 66
Study 38712616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccines
Number of subjects: 0
Study 38712895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 0
Study 38713024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascaded deep learning-based algorithm for intraprostatic lesion detection and segmentation.
Number of subjects: 658
Study 38713024 — intervention group
Group type: COMPARATOR
Intervention: Radiologist readings.
Number of subjects: 658
Study 38713047 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with lung damage
Number of subjects: 0
Study 38713063 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring with feedback (SM + FB)
Number of subjects: 0
Study 38713063 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38713137 — intervention group
Group type: EXPERIMENTAL
Intervention: 4L-PEG+1d-Lin
Number of subjects: 502
Study 38713137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L-PEG+3d-Lin
Number of subjects: 502
Study 38713137 — intervention group
Group type: COMPARATOR
Intervention: 4L-PEG
Number of subjects: 502
Study 38713137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L-PEG+1d-Lin
Number of subjects: 502
Study 38713137 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 502
Study 38713142 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartfulness meditation (HFM)
Number of subjects: 30
Study 38713205 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every three weeks)
Number of subjects: 60
Study 38713205 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib plus toripalimab
Number of subjects: 60
Study 38713231 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic intervention
Number of subjects: 54
Study 38713231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 38713248 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 166
Study 38713274 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 175
Study 38713274 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 negative patients
Number of subjects: 175
Study 38713475 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Number of subjects: 46
Study 38713475 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 46
Study 38713500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for PVCs, delivered over 10 weeks via videoconference with online text-based information and homework assignments.
Number of subjects: 19
Study 38713500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for PVCs
Number of subjects: 19
Study 38713508 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-assisted 6-minute walk test (6MWT)
Number of subjects: 200
Study 38713508 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-assisted Timed Up and Go test (TUG)
Number of subjects: 200
Study 38713508 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program
Number of subjects: 200
Study 38713508 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices (Verily Study Watch and Modus StepWatch)
Number of subjects: 200
Study 38713508 — intervention group
Group type: COMPARATOR
Intervention: Standardized questionnaires and tests (6MWT and TUG)
Number of subjects: 200
Study 38713581 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical and nonclassical monocytes, analyzed using single-cell RNA sequencing and pathway analyses.
Number of subjects: 0
Study 38713581 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic targets for chronic critical illness risk.
Number of subjects: 0
Study 38713595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (CAR T-cell therapy)
Number of subjects: 97
Study 38713611 — intervention group
Group type: COMPARATOR
Intervention: D2 lymphadenectomy
Number of subjects: 338
Study 38713611 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy + complete mesogastric excision
Number of subjects: 338
Study 38713673 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo RECOVER prospective cohort of children and young adults with and without previous or current infection (n = 6000)
Number of subjects: 10000
Study 38713673 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up for up to 4 years (Tier 2, n = 6000)
Number of subjects: 10000
Study 38713673 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep phenotyping subset of participants primarily the most severely affected by PASC (Tier 3, n = 600)
Number of subjects: 10000
Study 38713673 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth enrolled in the ABCD study (Tier 1)
Number of subjects: 10000
Study 38713818 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born in November
Number of subjects: 555
Study 38713818 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born in October
Number of subjects: 555
Study 38713818 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants meeting specific conditions (born in other months, at term, by vaginal delivery and without siblings)
Number of subjects: 555
Study 38713818 — intervention group
Group type: EXPERIMENTAL
Intervention: Other infants
Number of subjects: 555
Study 38713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry (MS) assessment of measurable residual disease (MRD) negativity during posttransplant therapy
Number of subjects: 138
Study 38713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PB/BM MRD negativity by MFC or NGS
Number of subjects: 138
Study 38713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained MS negativity
Number of subjects: 138
Study 38713888 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant MS assessment
Number of subjects: 138
Study 38713894 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen vaccination combined with PD-1 blockade
Number of subjects: 57
Study 38713894 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic long peptide vaccines targeting predicted high-quality neoantigens
Number of subjects: 57
Study 38713909 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-assisted weight management app (eTRIP)
Number of subjects: 0
Study 38714105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity (AMP) intervention
Number of subjects: 88
Study 38714105 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 88
Study 38714144 — intervention group
Group type: EXPERIMENTAL
Intervention: NSSI participants
Number of subjects: 117
Study 38714422 — intervention group
Group type: EXPERIMENTAL
Intervention: topical promestriene for 90 days (n=17)
Number of subjects: 62
Study 38714422 — intervention group
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser treatment (n=24)
Number of subjects: 62
Study 38714422 — intervention group
Group type: EXPERIMENTAL
Intervention: microablative fractional radiofrequency treatment (n=21)
Number of subjects: 62